New drug aims to stop relapses in kids with rare brain disease
NCT ID NCT05346354
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests the drug ravulizumab in 12 children and teens with a rare autoimmune disease called NMOSD, which causes attacks on the brain and spinal cord. The goal is to see if the drug can reduce the number of relapses and slow disability over about a year. Participants receive the drug by IV every 4 to 8 weeks, and researchers track their relapse rates and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Washington D.C., District of Columbia, 20010, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Edmonton, Alberta, T6G 1C9, Canada
-
Research Site
Toronto, Ontario, M5G 1X8, Canada
-
Research Site
Montreal, Quebec, H3T1C5, Canada
-
Research Site
Le Kremlin-Bicêtre, 94270, France
-
Research Site
Marseille, 13005, France
-
Research Site
Chieti, 66013, Italy
-
Research Site
Gallarate, 21013, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Yokohama, 232-0024, Japan
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Esplugues de Llobregat, 8950, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravulizumab (Ultomiris)
What this could lead to
If it works, this could provide a treatment option to reduce relapses and disability in children with NMOSD.
What could go wrong
This is a small, early-phase trial with only 12 participants and no placebo group, so results may not apply broadly. Risks include infusion reactions and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.